
Visceral adipose tissue is the fat stored around the abdominal organs, and it behaves differently from subcutaneous fat. It is metabolically active, contributes to insulin resistance and inflammation, and is more strongly associated with cardiometabolic risk than overall weight. Tesamorelin is a growth hormone releasing hormone analog originally developed and FDA-approved under the brand name Egrifta for reducing excess visceral abdominal fat in patients with HIV-associated lipodystrophy. Use outside that indication is off-label, and we will say so directly. At Bodyloom Wellness in Frisco, Texas, it is prescribed only after laboratory evaluation and a clinical discussion of what the evidence does and does not support for you.



Your journey begins with a consultation covering health history, medications, metabolic markers, and goals. Your provider will explain what the clinical evidence supports and how your situation compares to the studied population, so you can make the decision with real information in front of you.
We order comprehensive bloodwork before prescribing, including IGF-1, fasting glucose, HbA1c, a lipid panel, and relevant hormone markers. Your provider reviews the results with you and confirms whether Tesamorelin is appropriate before anything is written.
If it is appropriate, your provider writes the prescription and a pharmacy dispenses it. You will be taught to reconstitute and self-administer the daily subcutaneous injection, including site rotation and correct storage. Dosing is daily and consistency matters more than timing.
Follow-up appointments and repeat labs, including glucose markers, track your response. Meaningful change in visceral fat develops across months rather than weeks, consistent with how it was measured in trials. Your provider reassesses at defined intervals and will stop the protocol if it is not delivering.

Tesamorelin pricing is dose dependent. Your protocol and therefore your cost follow from your labs, your goals, and the dosing your provider prescribes. Lab work and follow-up visits are priced separately. Bodyloom VIP Members receive preferred rates, and financing is available through Cherry and CareCredit.

Yes, as Egrifta, for reducing excess visceral abdominal fat in patients with HIV-associated lipodystrophy. Prescribing it for other patients is off-label. Off-label prescribing is legal and common in medicine, but you deserve to hear it stated plainly rather than have the approval implied to cover every use.
Both are GHRH analogs, but Tesamorelin has a substantially stronger clinical trial record and an FDA approval behind it, and its studied effect is specific to visceral fat. Sermorelin is more commonly used for sleep, recovery, and general growth hormone support. Your goal determines which is the sensible choice.
Tesamorelin was studied for visceral fat, the fat around your organs, rather than for scale weight. If overall weight loss is your goal, a GLP-1 protocol is likely the better fit and we can build that plan with you instead.
Pricing is dose dependent and quoted after your consultation and lab review, since your protocol determines your cost. Lab work and follow-up visits are priced separately. VIP Members receive preferred rates.
Growth hormone activity can reduce insulin sensitivity, which is a documented consideration with this class. We check fasting glucose and HbA1c at baseline and on follow-up. Patients with diabetes or impaired glucose metabolism need specific evaluation before starting.
A daily subcutaneous injection you give yourself at home. We teach reconstitution, injection technique, site rotation, storage, and disposal before you begin. Consistency day to day matters more than the specific time of day.
Months, not weeks. The published trials measured change over that timescale, and your experience should be expected to follow it. Your provider will set a defined reassessment point rather than leaving you on an open-ended protocol.
It is contraindicated in pregnancy and in patients with active malignancy or disruption of the hypothalamic-pituitary axis. Patients with diabetes, a cancer history, or pituitary conditions require physician evaluation first. That review happens as part of your consultation and lab work.
You may contact the Texas Medical Board to verify the Medical Director's license status and for questions or to file a complaint.
Texas Medical Board, MC 263
P.O. Box 2018, Austin, TX 78768-2018
Phone: (800) 201-9353
Fax: (888) 512-2581
Website: www.tmb.state.tx.us
Usted puede comunicarse con la Junta Médica de Texas para verificar el estado de la licencia y para hacer preguntas o presentar una queja.
Junta Médica de Texas, MC 263
P.O. Box 2018, Austin, TX 78768-2018
Teléfono: (800) 201-9353
Fax: (888) 512-2581
Sitio web: www.tmb.state.tx.us